SCHEMBL589961

SCHEMBL589961

COc1c(-c2ccc(CN3CCCCC3)cc2)ccc2c(=O)c3c(=O)[nH]sc3n(C3CC3)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 1/20 0.41
AURKA O14965 1/20 0.41
CHUK O15111 1/20 0.41
MAPK13 O15264 1/20 0.41
DAPK3 O43293 1/20 0.41
PRKCG P05129 1/20 0.41
PIM1 P11309 1/20 0.41
CDK2 P24941 1/20 0.41
MARK3 P27448 1/20 0.41
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
GSK3A P49840 1/20 0.41
NEK2 P51955 1/20 0.41
PLK1 P53350 1/20 0.41
MAPK12 P53778 1/20 0.41
CDK5 Q00535 1/20 0.41
PRKCD Q05655 1/20 0.41
PAK1 Q13153 1/20 0.41
STK3 Q13188 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383382 0.92 IKBKB (0.41) IKBKBAURKACHUKMAPK13DAPK3
SCHEMBL2384494 0.92 IKBKB (0.40) IKBKBAURKACHUKMAPK13DAPK3
SCHEMBL3389481 0.88
SCHEMBL590844 0.88 IKBKB (0.45) IKBKBAURKACHUKMAPK13DAPK3
SCHEMBL2382135 0.87 IKBKB (0.44) IKBKBAURKACHUKMAPK13DAPK3
SCHEMBL12250242 0.84 IKBKB (0.42) IKBKBAURKACHUKMAPK13DAPK3
SCHEMBL2385588 0.84 IKBKB (0.42) IKBKBAURKACHUKMAPK13DAPK3
SCHEMBL12250218 0.82
Hydrochloric Acid SCHEMBL2383294 0.81
SCHEMBL12250253 0.80

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8114888-B2 Isothiazoloquinolones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2012-02-14 US claimed
EP-1848723-B1 NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS INC (US) 2010-12-15 EP claimed
US-20060235041-A1 New isothiazoloquinolones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. 2006-10-19 US claimed
US-20120114601-A1 NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-10 US disclosed
US-20120114601-A1 NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-10 US disclosed
US-8114888-B2 Isothiazoloquinolones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
US-8114888-B2 Isothiazoloquinolones and related compounds as anti-infective agents ACHILLION PHARMACEUTICALS, INC. (US) 2012-02-14 US disclosed
EP-1848723-B1 NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS INC (US) 2010-12-15 EP disclosed
EP-1848723-B1 NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS ACHILLION PHARMACEUTICALS INC (US) 2010-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235041-A1 New isothiazoloquinolones and related compounds as anti-infective agents TOP1, RECQL, IRF3 IKBKB 350/4885AURKA 895/4885CHUK 131/4885
US-20120114601-A1 NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS TOP1, RECQL, IRF3 IKBKB 350/4885AURKA 895/4885CHUK 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.